REGENXBIO Inc. announced fresh, encouraging interim results on safety and efficacy from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 in Duchenne muscular dystrophy patients aged 1 to 11 years.

Elranatamab, marketed under the brand name Elrexfio, is FDA approved. It received FDA approval for the treatment of adults with multiple myeloma.

Health Canada has authorized the use of Celltrion's Steqeyma®, a biosimilar of Stelara® (ustekinumab), for managing various persistent inflammatory diseases.

Talquetamab, marketed under the brand name Talvey, is FDA approved. It received approval for the treatment of adults with multiple myeloma.

Aug 6th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Izervay, which is the brand name for avacincaptad pegol, received FDA approval on August 4, 2023.

Vaccinex Announces Promising Results from SIGNAL-AD Phase 1b/2 Trial of Pepinemab for Alzheimer's Disease.

Zuranolone, marketed under the brand name Zurzuvae, is approved by the FDA for the treatment of postpartum depression (PPD) in adults.

Myeloid Therapeutics begins administering MT-303, a new RNA CAR targeting GPC3, in a Phase 1 trial for late-stage hepatocellular carcinoma (HCC).

Lotilaner ophthalmic, marketed under the brand name Xdemvy, has been approved by the FDA for the treatment of Demodex blepharitis.

SanBio Gains Approval for "AKUUGO® Suspension for Intracranial Use" (INN: Vandefitemcel) to Treat Persistent Motor Paralysis from Traumatic Brain Injuries.

Donislecel, branded as Lantidra, was approved by the FDA on June 28, 2023. It represents a significant development in the treatment of type 1 diabetes.